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Background/Aims: Endoscopic vacuum-assisted closure 
(EVAC) has been attempted as new nonsurgical treatment 
for anastomotic leakage. We aimed to evaluate the clinical 
outcomes of EVAC and compare its efficacy with the self-ex-
pandable metallic stent (SEMS) for postgastrectomy leakage. 
Methods: Between January 2007 and February 2018, 39 
patients underwent endoscopic treatment for anastomotic 
leakage after gastric cancer surgery. Of them, 28 patients 
were treated with SEMS, seven with EVAC after SEMS fail-
ure, and four with EVAC. We retrospectively compared the 
clinical characteristics and therapeutic outcomes between 
EVAC (n=11) and SEMS (n=28). Results: The median follow-
up duration was 17 months (interquartile range, 9 to 26 
months) in both groups. In comparison of clinical character-
istics between two groups, only the median size of the leak 
was larger in the EVAC group than in the SEMS group (2.1 
cm vs 1.0 cm; p<0.001). All EVAC cases healed successfully; 
however, two cases (7.1%) failed to heal in the SEMS group. 
Anastomotic stricture occurred one case (9.1%) in EVAC and 
four cases (14.3%) in SEMS within 1 year after endoscopic 
treatment. The median treatment duration of EVAC was 
shorter than that of SEMS (15 days vs 36 days; p<0.001). 
Median weight loss after therapy was similar in both groups 
(8.0 kg in EVAC vs 9.0 kg in SEMS; p=0.356). Conclusions: 
EVAC can be effective endoscopic treatment for postgas-
trectomy anastomotic leakage. Substantial leakage could 
be an important clinical factor for considering EVAC as 
a treatment option. Large randomized controlled trials 
are needed to confirm the efficacy of EVAC. (Gut Liver 
2020;14:746-754)
Key Words: Vacuum assisted closure; Anastomotic leak; 
Gastrectomy; Self-expandable metallic stents; Stomach neo-
plasms
INTRODUCTION
Surgical resection is the only curative treatment for advanced 
gastric cancer or early gastric cancer that is not eligible for endo-
scopic submucosal dissection. Despite advances in surgical tech-
niques, postoperative anastomotic leak is still the main reported 
adverse event, with an incidence rate of 0.7% to 7.5%1-7 and mor-
tality rate of 0.01% to 2.4%.1,4,6,7 In postoperative anastomotic 
leak in upper gastrointestinal surgery, nonsurgical treatment 
or even conservative management has shown better outcomes 
than reoperation.7 Endoscopic clipping, fibrin glue injection, and 
self-expandable metallic stent (SEMS) insertion have been used 
as nonsurgical endoscopic methods for the treatment of anas-
tomotic leak,8-12 however, the use of each modality has been 
limited by various clinical factors. Among those methods, SEMS 
insertion has been reported to have a favorable treatment suc-
cess rate (>68.8% to 89.0%) for postoperative anastomotic leak 
in esophageal cancer.13-17 However, adverse events after SEMS 
treatment have also been reported, such as migration, failure of 
stent extraction, and stricture formation after stent removal.16-20 
In recent years, endoscopic vacuum-assisted closure (EVAC) 
has been attempted as a new treatment option for postopera-
tive fistula or anastomotic leak.21 Several studies have reported 
the efficacy of EVAC in post-esophageal surgery, with a suc-
cess rate of 84.4% to 86.4%.22-24 By comparison, little has been 
reported on the efficacy of EVAC treatment for postgastrectomy 
anastomotic leak. In this study, we reviewed the clinical charac-
teristics and therapeutic outcomes of patients who were treated 
with EVAC or SEMS for postgastrectomy anastomotic leak and 
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compared the efficacy of EVAC with that of SEMS.
MATERIALS AND METHODS
1. Patients
Between January 2007 and February 2018, total 93 cases 
of anastomotic leak occurred after upper gastrointestinal tract 
surgery at Yonsei University Severance Hospital. Among them, 
75 cases occurred after gastrectomy in gastric cancer surgery. 
Of them, 14 cases received the conservative management 
or reoperation, 22 cases were treated with clipping with or 
without fibrin glue or histoacryl, and 39 cases were treated with 
SEMS or EVAC. We retrospectively reviewed of 39 patients 
who underwent SEMS or EVAC for postoperative anastomotic 
leak. In our center, SEMS was the main treatment method 
for anastomotic leak from 2010 to 2015. Since October 2015 
when the endoscopic vacuum therapy was introduced at our 
center, EVAC has been tried for anastomotic leak of upper 
gastrointestinal tract and mainly performed to the cases that 
failed with SEMS. Since the end of 2016, EVAC has been used 
in an initial treatment of anastomotic leak for some cases that 
endoscopists judged unsuitable for mounting SEMS, such 
as a large leak size or a structural deformation at subtotal 
gastrectomy (STG).
Among a total of 39 patients, 28 cases were treated with 
SEMS and 11 cases with EVAC. For the EVAC cases, four 
cases were treated with EVAC alone and seven cases were 
switched from SEMS to EVAC during treatment because they 
were suspected of treatment failure. We compared the clinical 
characteristics and therapeutic outcomes between the EVAC 
group (n=11) and the SEMS group (n=28).
2. Assessment of leak diagnosis and treatment outcome
When clinical symptoms such as abdominal pain, increasing 
amount of drainage, fever, leukocytosis, and elevation of 
C-reactive protein level occurred after surgery, anastomotic leak 
was suspected. Further, radiological examinations (abdominal 
computed tomography [CT], esophagography) and endoscopy 
were performed to confirm the leak. Radiologic findings 
indicative of leak were defined as extraluminal extravasation 
of contrast medium on fluoroscopy or CT or the presence of 
infiltration around the anastomosis site with or without fistula 
tract formation on CT. Endoscopic treatment was performed 
only if leak was confirmed on endoscopy.
The primary endpoint was the success or failure of leak clo-
sure. Successful leak closure was defined as no evidence of the 
leak on the radiologic or endoscopic image after device removal, 
and no clinical sign of persistent leak. The therapeutic outcomes 
were evaluated using the following factors: success rate of leak 
closure, leak-related mortality, duration of therapy, reposition-
ing or replacement count of stent or vacuum, weight loss after 
treatment, antibiotics use, and incidence rate of stricture within 
1 year. The duration of therapy was defined as the number of 
days from device insertion to removal. Leak-related mortality 
was defined as death of the patient before the confirmation of 
leak closure without other causes of death.
3. Endoscopic SEMS 
In all patients, the endoscopic procedure was performed under 
sedation, using standard upper gastrointestinal endoscopes (GIF 
Q260 and H260, 290; Olympus, Tokyo, Japan), with fluoroscopic 
assistance. The endoscopist first checked the location of the 
anastomotic leak through the endoscope and then injected 
contrast dye to the leak site. If the dye passed through the leak, 
the size of the leak was measured based on the diameter of 
the endoscope. After the leak was confirmed on endoscopy, 
the location of the leak was marked using radiopaque material 
attached on the patient’s skin, and the guidewire was passed 
into the endoscope channel. Then, the stent was inserted 
along the guidewire and deployed over the leak area under the 
guidance of radiofluoroscopic imaging. We usually use Shim’s 
technique to prevent the migration of the stent.25 According 
to Shim’s technique, the stent was fixated using a silk thread 
covered with a 14-F rubber tube. The end of the silk thread was 
attached to the proximal edge of stent and connected to the 
patient’s earlobe via the nostril.25 Endoscopy was repeated at 1 
to 2 weeks after insertion, and if there was no migration, the 
external fixation was removed. The stent position was checked 
with abdominal X-ray at the day after the procedure and every 
1 to 2 weeks until the stent was stabilized. If the migration of 
stent was suspected on X-ray or the patient’s symptom was 
aggravated, endoscopic evaluation was performed any time 
and the stent was changed or repositioned if needed. The 
nutritional support was provided by total parenteral nutrition 
(TPN) first and switched to per oral intake at 2 to 3 days after 
stent insertion. The stent was removed within 4 to 8 weeks and 
complete closure of the anastomotic leak was confirmed with 
endoscopy with fluoroscopy and/or with CT or esophagography 
after stent removal. 
4. Endoscopic vacuum-assisted closure
In all patients, the endoscopic procedure was performed under 
sedation, using standard upper gastrointestinal endoscopes (GIF 
Q260 and H260, 290; Olympus), with fluoroscopic assistance. 
The endoscopist first checked the location of the anastomotic 
leak through the endoscope and then injected a contrast dye to 
the leak site. If the dye passed through the leak, the size of the 
leak was measured based on the diameter of the endoscope. Two 
expert endoscopists (J.C.P. and S.K.L.) performed the endoscopic 
interventions.
After the assessment of the leak size and location, a poly-
urethane foam sponge (e.g., CuraVAC®; CGBio Inc., Seongnam, 
Korea) was cut by the endoscopist into the adequate size and 
shape. To apply negative suction pressure through the sponge, 
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additional 1 to 2 mm side holes were made at the nasogas-
tric (NG) tube tip by using scissors. Then, the NG tube tip was 
placed into one nostril and extracted out through the oral cavity 
by using alligator forceps (MTW Endoskopie, Wesel, Germany). 
Size-adjusted (15 to 30 mm) polyurethane sponge was anchored 
at the NG tube tip by suture with a 3-way nylon thread. Then, 
the NG tube tip with sponge was gripped with alligator forceps 
and pushed into the necrotic portion of the leak site through 
the endoscopic view (Fig. 1A and B). The sponge was buried 
in the hole to completely cover with the area of cavity. After 
positioning, the outside part of the NG tube was fixed at the 
patient’s nose by taping. Finally, the outside tip of the NG tube 
was connected to an electronic vacuum device (KCI V.A.C. 
Freedom®; KCI USA Inc., San Antonio, TX, USA; setting: –125 
mm Hg, continuous, and high intensity), and continuous suc-
tion pressure (100 to 125 mm Hg) was generated. We evaluated 
the wound status through endoscopy at weekly intervals until 
the wound cavity seemed to be firmly closed. If the sponge size 
and position were considered appropriate on the endoscopy, 
the sponge was not changed and re-fixed in the same position. 
If the sponge size became larger than the leak size according 
to wound healing, the previous sponge was removed and the 
resized sponge was newly inserted. If the clinical symptom was 
aggravated or if sponge migration was suspected on X-ray, 
endoscopic evaluation was performed earlier than the regular 
schedule. EVAC therapy was terminated when the leak size be-
came too small to place further sponge or the granulation tissue 
was filled up enough the hole (Fig. 1C). Complete healing of the 
leak was evaluated using endoscopy with fluoroscopy and/or 
CT or esophagography. The initial nutritional supplement was 
provided through TPN and switched to enteral feeding after the 
EVAC sponge was removed. 
5. Switching to EVAC from endoscopic SEMS
The endoscopist considered switching SEMS to EVAC in the 
following conditions: if the leak hole was not changed on the 
subsequent endoscopy after SEMS insertion (Fig. 2), if the drain 
of Hemovac® (Zimmer Surgical, Inc., Dover, OH, USA) was 
continuously turbid, if the clinical inflammation signs were not 
improved (fever, elevation of C-reactive protein, etc.), or if the 
reposition or replacement of the stent was needed more than 
two times.
6. Statistical analysis
Data are presented as medians with ranges for continuous 
variables and as numbers for categorical variables. Continu-
ous variables were evaluated using the Mann-Whitney test. 
Categorical variables were evaluated with the chi-square test or 
A B C
Fig. 1. Case treated with endoscopic vacuum-assisted closure (EVAC) only. (A) Anastomotic leakage after Billroth I surgery was detected. (B) An 
EVAC sponge was inserted at the leakage site. (C) After 2 weeks, granulation tissue formed at the leakage hole.
A B C D
Fig. 2. Case treated with endoscopic vacuum-assisted closure (EVAC) after the failure of self-expandable metallic stents (SEMSs). (A) Anastomotic 
leakage was detected after Billroth I surgery and SEMS was initially inserted. (B) After 2 weeks, leakage was still observed without significant 
changes. (C) A sponge was prepared and mounted into the hole by using alligator forceps. (D) After 13 days, healing with granulation tissue was 
seen after EVAC sponge removal.
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Fisher exact test because of small sample sizes.
Statistical analysis was performed using IBM SPSS software, 
version 23.0 for Windows (IBM Corp, Armonk, NY, USA). All 
statistical tests were two-sided, and a value of p<0.05 was con-
sidered statistically significant.
RESULTS
1. Characteristics of patients
Of 39 patients, 11 cases were treated with EVAC and 28 cases 
were treated with SEMS. Seven cases of EVAC-treated patients 
were the cases of changed from SEMS to EVAC due to no 
improvement in clinical symptoms. The other four cases were 
initially treated with EVAC because the clinician determined 
that EVAC therapy was appropriate for the lesions. The clinical 
characteristics of the 39 patients (11 of EVAC group, 28 of 
SEMS group) are shown in Table 1. Age, American Society of 
Anesthesiologists score, underlying comorbidities, anticoagulant 
or antiplatelet agents use, type of surgery, TNM stage, and 
preoperative body mass index showed no statistically significant 
differences between two groups. Only the median size of leak 
was larger in EVAC group than SEMS group (p<0.001).
2. Therapeutic outcome of patients
The median follow-up duration were 11 months (interquar-
tile range [IQR], 1.0 to 17.0 months) in EVAC group and 19.5 
months (IQR, 10.3 to 35.0 months) in SEMS group. The thera-
peutic outcomes of each treatment are shown in Table 2, and 
detailed data of the EVAC group are shown in Table 3. 
All cases of EVAC were treated successfully without mortality 
(11/11, 100%). In comparison, there were two cases of treatment 
failure (2/28, 7.1%) including one case of mortality (1/28, 3.6%) 
in SEMS group. One patient died of a leak associated infectious 
complication on the 23rd day after stent insertion without clini-
cal improvement. The other patient removed stent on 17th day 
of insertion due to exacerbation of clinical inflammatory symp-
tom and sign. After stent removal, the leak was still confirmed, 
however, the patient refused further treatment and expired 9 
months later. 
The success rate of SEMS was 92.9% (26/28), however, when 
the seven cases, which switched from SEMS to EVAC, were con-
sidered as SEMS failure, the success rate of SEMS was 74.3% 
(26/35).
The duration of therapy in EVAC group was significantly 
shorter than SEMS group (median, 15 days [IQR, 6 to 21 days] 
vs 36 days [IQR, 28 to 48 days]; p<0.001). 
In the number of reposition or replacement procedures, there 
were five cases in EVAC due to sponge migration out or hole 
size change (5/11, 45.5%) and seven cases in SEMS due to stent 
migration (7/28, 25.0%; p=0.262). 
In calculating the weight change from the time of admission 
to the first outpatient department visit on discharge, the median 
weight loss was no significant difference between two groups 
(median, 8.0 kg [IQR, 4.0 to 11.0 kg] in EVAC group vs 9.0 kg 
[IQR, 7.0 to 12.0 kg] in SEMS group; p=0.356).
All patients received antibiotic therapy during procedure. 
The antibiotics were started immediately when the leak was 
confirmed or clinically suspected, and continued until the leak 
was completely closed. However, one case that switched to 
EVAC from SEMS stopped the antibiotic during EVAC therapy 
Table 1. Comparison of Clinical Characteristics between the EVAC and SEMS Groups Treated for Anastomotic Leakage
Characteristic Total (n=39) EVAC (n=11) SEMS (n=28) p-value
Age, yr 66.0 (39–82) 68.0 (55–81) 63.5 (39–82) 0.450
ASA
  1 or 2 24 (61.5) 6 (54.5) 18 (64.3) 0.718
  3 or 4 15 (38.5) 5 (45.5) 10 (35.7) 0.718
Cardiovascular disease 23 (59.0) 9 (81.8) 14 (50.0) 0.086
Diabetes mellitus 10 (25.6) 4 (36.4) 6 (21.4) 0.424
Use of anticoagulant or antiplatelet agent 14 (35.9) 6 (54.5) 8 (28.6) 0.156
Type of surgery
  Total or proximal gastrectomy 28 (73.7) 6 (54.5) 22 (78.6) 0.234
  Billroth I or II 11 (28.2) 5 (45.5) 6 (21.4) 0.234
TNM stage
  1 or 2 27 (69.2) 9 (81.8) 18 (64.3) 0.446
  3 or 4 12 (30.8) 2 (18.2) 10 (35.7) 0.446
Preoperative BMI, kg/m2 24.5 (21.2–26.4) 23.8 (19.8–25.4) 24.6 (22.1–26.5) 0.363
Size of leak, cm 1.5 (1.0–2.0) 2.1 (2.0–3.0) 1.0 (0.8–1.5) <0.001
Data are presented as median (interquartile range) or number (%).
EVAC, endoscopic vacuum-assisted closure; SEMS, self-expandable metallic stent; ASA, American Society of Anesthesiologists; BMI, body mass 
index.
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Table 2. Comparison of Therapeutic Outcomes between EVAC and SEMS for Anastomotic Leakage
Outcomes Total (n=39) EVAC (n=11) SEMS (n=28) p-value
Follow-up duration, mo 17.0 (9.0–26.0) 11.0 (1.0–17.0) 19.5 (10.3–35.0) 0.043




Leak-related mortality 1 (2.6) 0 1 (3.6) >0.999
Duration of therapy, day 31.0 (15.0–46.0) 15.0 (6.0–21.0) 36.0 (28.0–48.0) <0.001
Stent/sponge change or replacement 12 (30.8) 5 (45.5) 7 (25.0) 0.262
Weight loss after treatment, kg† 9.0 (6.8–12.0) 8.0 (4.0–11.0) 9.0 (7.0–12.0) 0.356
Antibiotics use
  Antibiotics cessation 1 (2.6) 1 (9.1) 0 0.282
  Antibiotics duration, day 24.0 (16.0–36.0) 29.0 (15.0–47.0) 23.5 (16.3–34.5) 0.731
  Antibiotics step-up 11 (43.6) 0 11 (39.3) 0.017
  Antibiotics step-down 3 (7.7) 2 (18.2) 1 (3.6) 0.187
Incidence rate of stricture within 1 yr 5 (12.8) 1 (9.1) 4 (14.3) >0.999
Data are presented as median (interquartile range) or number (%).
EVAC, endoscopic vacuum-assisted closure; SEMS, self-expandable metallic stent.
*Value when seven cases were switched from SEMS to EVAC and classified as SEMS failure; †Except one mortality case.
























1 M/68 Yes PG with DTR T1bN0
AWD
2.0 Yes 46 16 Yes 362 No
2 M/56 Yes TG with RY T1bN0
AMD
2.1 Yes 6 15 No 361 No
3 M/74 Yes PG with DTR T1bN0
AMD
2.5 Yes 12 21 Yes 523 No
4 M/55 Yes PG with DTR T1aN0
AMD
3.0 Yes 21 6 No 748 No
5 M/58 Yes PG with DTR T1bN0
APD
3.3 Yes 38 15 Yes 718 Yes
6 M/80 Yes TG with RY T4N3
APD
2.0 Yes 16 23 Yes 530 No
7 M/81 Yes STG-BI T1bN1
APD
3.0 Yes 12 13 No 246 No
8 F/65 No STG-BI T1aN0
SRC
2.0 Yes NA 6 No 27 No
9 M/63 No STG-BI T1bN0
AMD
2.5 Yes NA 13 No 367 No
10 F/68 No STG-BII T4N3
APD
2.0 Yes NA 17 Yes 30 No
11 M/70 No STG-BI G3N0
NET
1.5 Yes NA 6 No 55 No
EVAC, endoscopic vacuum-assisted closure; SEMS, self-expandable metallic stent; M, male; F, female; PG, proximal gastrectomy; DTR, double 
tract reconstruction; TG, total gastrectomy; RY, Roux-en Y esophagojejunostomy; STG-BI, subtotal gastrectomy with gastroduodenostomy; STG-
BII, subtotal gastrectomy with gastrojejunostomy; AWD, adenocarcinoma, well-differentiated; AMD, adenocarcinoma, moderately differentiated; 
APD, adenocarcinoma, poorly differentiated; SRC, signet ring cell carcinoma; NET, neuroendocrine tumor; NA, not available.
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and achieved the leak healing without further antibiotic use. 
The duration of antibiotic use showed no significant differ-
ence between two groups (median, 29.0 days [IQR, 15.0 to 47.0 
days] in EVAC group and 23.5 days [IQR, 16.3 to 34.5 days] in 
SEMS group; p=0.731). Within a certain period of time after 
the procedure, when the patient’s signs of infection were not 
improved such as sustained of fever, leukocytosis, or C-reactive 
protein elevation, the clinicians usually decided to give step-up 
antibiotic therapy. In SEMS group, 11 patients received step-up 
antibiotic therapy during the treatment period (11/28, 39.3%). In 
comparison, in EVAC group, all patients did not receive step-up 
antibiotic therapy during the treatment period.
After the therapy, five cases of anastomosis site stricture oc-
curred during follow-up period. All cases developed within 1 
year. In the EVAC group, one case of anastomotic stricture  oc-
curred (1/11, 9.1%) at 147 days after EVAC removal. He under-
went two sessions of through-the-scope endoscopic dilations, 
and the clinical symptom resolved without adverse events or 
sequelae (Fig. 3). In the SEMS group, four cases of anastomotic 
stricture occurred (4/28, 14.3%) at a median of 102 days (IQR, 
41.3 to 270.8 days) after SEMS removal. The details of each case 
are described in Table 4.
DISCUSSION
EVAC was first introduced as a treatment for anastomotic 
leak after rectal surgery.21 Since the first report of its application 
in the upper gastrointestinal tract,26,27 several centers have re-
ported the feasibility and efficacy of EVAC management.22,24,28-30 
However, most of those studies focused on esophageal cancer 
surgery, and there have been very few studies on leak treatment 
after gastric cancer surgery. To the best of our knowledge, this is 
the first study to report the clinical outcome of EVAC focusing 
in the treatment of postgastrectomy anastomotic leak in gastric 
cancer.
In our study, there was no significant difference in success 
rate between EVAC and SEMS. However, the duration of EVAC 
therapy was significantly shorter than that of SEMS therapy 
even if the leak size was larger in the EVAC group than in the 
SEMS group. Concerning the treatment mechanism, SEMS in-
sertion simply blocks the leak site until the healing of the leak, 
but EVAC drains the necrotic debris and pus in the leak site 
with negative pressure.21 Therefore, EVAC can prevent the lo-
cal spread of inflammation, and induce vascular perfusion and 
granulation tissue formation. These advantages may be related 
to the rapid healing process after EVAC.
In previous studies, a leak size of >2 cm has been suggested 
A B C
Fig. 3. A case of stricture development after treatment. (A) Anastomosis site stricture occurred at 147 days after leakage healing. (B) Two through-
the-scope endoscopic dilations were done at an interval of 3 months. (C) The symptoms were relieved 2 weeks later after the last procedure, and 
an improved state of stricture was confirmed with endoscopy 1 year later.







Duration of leak 
treatment, day









1 M/61 SEMS 21 126 3 7, 12 750 Improved but still remained
2 M/74 SEMS 46 78 3 1, 2 808 Resolved
3 F/66 SEMS 28 29 3 1, 4 286 Follow-up loss*
4 M/48 SEMS 35 319 1 NA 380 Follow-up loss*
5 M/58 SEMS→EVAC 38, 15 147 2 3 718 Resolved
EVAC, endoscopic vacuum-assisted closure; SEMS, self-expandable metallic stent; TTS, through the scope; M, male; F, female; NA, not available.
*Follow-up loss after the last procedure.
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to indicate the failure of endoscopic treatment.12 In our study, 
the median leak size of 11 patients who were successfully 
treated with EVAC was 2.1 cm (IQR, 2.0 to 3.0 cm). Among 
them, seven patients had a leak size of ≥2 cm and three patients 
had a leak size of ≥3 cm. By comparison, in the 26 patients 
who were successfully treated with SEMS, the median leak size 
was 1.0 cm (IQR, 0.8 to 1.5 cm), and among them, particularly 
two patients with a leak size more than 2 cm were treated for 
relatively longer period (46 days each). Generally, a large leak 
needs more time to achieve for granulation tissue formation 
and leak closure. As mentioned above, EVAC may shorten this 
period through its therapeutic mechanism.
A total of 11 cases of leak occurred after STG. One of them 
was successfully treated with EVAC after SEMS failure. Since 
then, the four subsequent cases of leak occurring after STG 
were initially treated with EVAC without SEMS because the 
endoscopist judged that EVAC could be better than SEMS. They 
were successfully treated with a median treatment duration 
of 9.5 days (IQR, 6.0 to 38.5 days). In other six patients who 
were treated with SEMS alone, the median treatment duration 
was 36.5 days (IQR, 16.3 to 63.0 days). Because the remnant 
stomach should be connected with small bowel, the channel at 
anastomosis site in the STG is wider and more curved than in 
the total gastrectomy. If the stent is inserted in this condition, 
a free space is formed between the stent and mucosa, and it is 
difficult to cover the leak area completely. However, because 
the shape and size of sponge can be controlled in EVAC, it 
can be directly inserted into the leak area and mounted at the 
hole. Therefore, EVAC may be less affected by postoperative 
structural change and have an advantage for STG cases.
Previous studies on EVAC therapy recommended vacuum 
sponge replacement every 3 to 7 days31,32 because the size of 
the leak cavity changes according to ingrowth of granulation 
tissue.33 Such frequent repetition of the endoscopic procedure 
was one of the limitations of EVAC therapy. In our study, we 
performed endoscopy at intervals of 1 to 2 weeks to check the 
leak state and if the sponge was adequate for size of the hole 
in endoscopic view, we did not change the sponge. Among 
11 cases of EVAC, six cases were treated successfully without 
sponge change during a median of 9.5 days (IQR, 6.0 to 13.5 
days).
All patients started to use antibiotics when the leak was 
strongly suspected to complicated by intra-abdominal infection. 
They maintained antibiotics until the treatment was completely 
finished, except for one patient, who ceased the antibiotics on 
the first day after switching to EVAC from SEMS. He achieved 
healing without further antibiotics use. During the antibiotics 
use, the clinician considered antibiotic step-up if the clinical 
symptom did not improve after the procedure (usually within 2 
to 3 days). In SEMS group, 11 of 28 patients received antibiotic 
step-up. By comparison, all patients of EVAC group were treated 
without antibiotic step-up. Among four patients who had 
received antibiotic step-up during SEMS therapy, two patients 
received antibiotic step-down during EVAC period. Moreover, 
although there was no statistically significant difference, in the 
SEMS group, 28.6% (8/28) of patients terminated antibiotics 
within 10 days prior to SEMS removal, whereas in the EVAC 
group, 54.5% (6/11) of patients terminated antibiotics within 
10 days prior to EVAC removal. Although the effect of previous 
SEMS therapy should be considered, it is expected that EVAC 
therapy may reduce antibiotics use through therapeutic 
mechanisms. However, more large-scaled prospective study will 
be needed for confirmation.
Pathophysiologically, local inflammation during the intestinal 
healing process may be related to the occurrence of stricture.34 
As mentioned above, the local inflammation is expected to be 
more in SEMS than EVAC. In addition, bleeding and ulceration 
can occur when SEMS is extracted, due to tissue hyperplasia 
and mucosal embedding at the stent tip.35 However, EVAC can 
minimize the contact area between the sponge and the normal 
mucosa through the size and shape adjustable, which can lower 
the incidence of posttreatment stricture in EVAC compared than 
SEMS.
In the previous studies, the nutritional support in EVAC 
therapy was done by TPN until the sponge was removed. In 
SEMS therapy, enteral feeding is possible within 1 to 2 days 
after. In our center, the patients with SEMS started enteral 
feeding within a week after stent insertion, and the patients 
with EVAC were supplied only TPN during therapy. To find the 
nutritional difference, we compared the body weight at pre-
operation and at first outpatient visit after discharge. In this 
study, there was no significant difference between the two 
groups. This suggests that although enteral feeding is delayed 
in EVAC, nutritional disadvantage may not be large. However, 
there should be large-scaled studies for the investigation of the 
nutritional aspect. 
This study has some limitations. First, this study was not a 
randomized controlled trial and the number of cases in each 
group was relatively small. Second, the cases that changed to 
EVAC from SEMS were included in EVAC group. Although 
these changes were made when SEMS treatment was considered 
to have failed, it is difficult to completely exclude the effect of 
SEMS on treatment extension.
Despite these limitations, we believe that our study presents 
the effectiveness of EVAC in a treatment technique of anasto-
motic leak after gastric cancer resection. Our study suggests a 
clinical situation in which EVAC can be considered first. 
In conclusion, EVAC can be another useful treatment option 
in the postgastrectomy anastomotic leak. Based on this study, 
we hope that further large prospective and comparative studies 
for SEMS and EVAC will be conducted to establish an efficient 
treatment for anastomotic leak after gastrectomy.
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